The present disclosure provides modified bacteria and modified peptidoglycan comprising modified D-amino acids; compositions comprising the modified bacteria or peptidoglycan; and methods of using the modified bacteria or peptidoglycan. The modified D-amino acids include a bioorthogonal functional group such as an azide, an alkyne or a norbornene group. Also provided are modified peptidoglycans conjugated to a molecule of interest via a linker.

The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and pain.

Peptides are provided herein, wherein the peptide bearing one or more amino acid sequence differences relative to SEQ ID NO: 1, with the amino acid sequence differences comprising at least one cysteine replacement.

Provided herein are compounds of Formula (I), as well as compositions comprising a compound of Formula (I) and uses thereof.

##STR00001##

The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/or impairment, pain, and traumatic brain injury.

Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.

The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B).sub.n (I) wherein M, T, B and n ore as defined in claim 1.

An adjuvant formulation includes a monophosphoryl Lipid A (MPLA) analogue, a Pam3CSK4 analogue, or a muramyldipeptide (MDP) analogue, or combinations thereof. The adjuvant may be formulated in soluble form or in a nanoparticle, such as polylactic glycolic acid nanoparticles. A vaccine formulation comprises the adjuvant formulation and an immunogen. Methods of vaccinating an animal include delivering the vaccine formulation to the animal.

This invention relates to collagen-binding synthetic peptidoglycans and engineered collagen matrices comprising a collagen matrix and a collagen-binding synthetic peptidoglycan where the collagen-binding synthetic peptidoglycan can be aberrant or can have amino acid homology with a portion of the amino acid sequence of a protein or a proteoglycan that regulates collagen fibrillogenesis. The invention also relates to kits, compounds, compositions, and engineered graft constructs comprising such collagen-binding synthetic peptidoglycans or engineered collagen matrices and methods for their preparation and use.

The present invention relates to a glycopeptide of the following formula I: or a tautomer, a stereoisomer or a mixture of stereoisomers thereof in any proportions, in particular a mixture of enantiomers, and particularly a racemate mixture, and/or a physiologically acceptable salt and/or solvate thereof, in which:—n represents an integer from 1 to 6,—m represents 0 or 1,10—p represents 0 or 1—R represents H, F, CH.sub.3, CH.sub.2F, or CH.sub.2OH,—R.sub.1, R.sub.2 and R.sub.3 represent, independently from one another, H, F, or OH,—R.sub.4 represents a hydrogen, a halogen, or OH,—R.sub.6 and R.sub.7 represent, independently from each other, a hydrogen, a (C.sub.1-C.sub.6)alkyl, an aryl, or an aryl-(C.sub.1-C.sub.6)alkyl, and—R.sub.8 represents H or a CO-(C.sub.1-C.sub.20)alkyl, useful for skin plumping and/or skin volumizing and/or skin densifying and/or wrinkle filling and/or skin or hair moisturizing and/or skin or hair relipiding and/or stimulation of hair growth and/or for the treatment of dry skin and/or atopic dermatitis and/or atopic eczema and/or psoriasis, due to its ability to increase lipid synthesis.

##STR00001##